Wall Street Bears Circle Sarepta: Sell Ratings Pile Up After Q4 Reset Warnings

Major analysts like Citi, Needham, and Bank of America maintain Sell ratings on Sarepta after recent updates, citing risks to key products like Elevidys, lower 2026 outlook, and regulatory concerns in Duchenne muscular dystrophy treatments.